A Phase 2 clinical trial showed good tolerability for ZYN002, with promising results in improving social avoidance behaviors specifically in a subgroup of patients with ≥90% FMR1 gene methylation, who typically experience more severe FXS symptoms [62]. The gene discussed is FMR1; the disease is fragile X syndrome.